

# WHO Expert Committee on Biological Standardization

---

Sixty-eighth report



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO *Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int); order on line: [www.who.int/bookorders](http://www.who.int/bookorders)).

W H O T e c h n i c a l R e p o r t S e r i e s  
1 0 1 1

# WHO Expert Committee on Biological Standardization

---

Sixty-eighth report

*This report contains the collective views of an international group of experts and  
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health  
Organization**

WHO Expert Committee on Biological Standardization: sixty-eighth report  
(WHO Technical Report Series, No. 1011)  
ISBN 978-92-4-121020-1  
ISSN 0512-3054

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO Expert Committee on Biological Standardization: sixty-eighth report. Geneva: World Health Organization; 2018 (WHO Technical Report Series, No. 1011). Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in Malta

# Contents

|   |      |
|---|------|
| <b>Abbreviations</b>  | xiii |
| <b>1. Introduction</b>  | 1    |
| <b>2. General</b>   | 3    |
| 2.1 Current directions  | 3    |
| 2.1.1 Strategic directions in the regulation of medicines and other health technologies   | 3    |
| 2.1.2 Vaccines and biotherapeutics: recent and planned activities in biological standardization   | 5    |
| 2.1.3 Blood products and in vitro diagnostics: recent and planned activities in biological standardization  | 8    |
| 2.2 Reports   | 10   |
| 2.2.1 Report from the WHO Blood Regulators Network  | 10   |
| 2.2.2 Report from the WHO network of collaborating centres on standardization and regulatory evaluation of vaccines                                       | 12   |
| 2.2.3 Report from the WHO network of collaborating centres for blood products and in vitro diagnostics  | 13   |
| 2.3 Feedback from custodian laboratories  | 13   |
| 2.3.1 Developments and scientific issues highlighted by custodians of WHO biological reference preparations   | 13   |
| 2.4 Cross-cutting activities of other WHO committees and groups   | 16   |
| 2.4.1 Update from the WHO Expert Committee on Specifications for Pharmaceutical Preparations  | 16   |
| 2.4.2 WHO Global Benchmarking Tool  | 17   |
| 2.4.3 Development of WHO guidelines on good regulatory practices  | 18   |
| 2.4.4 Snake-bite envenoming   | 19   |
| 2.4.5 Update from the WHO Product Development for Vaccines Advisory Committee   | 21   |
| 2.4.6 Pilot WHO prequalification of biosimilar monoclonal antibodies  | 22   |
| 2.4.7 Model NRA Lot Release Certificate for prequalified vaccines   | 23   |
| 2.4.8 Planned proficiency testing study of a standardized method for determining total and free saccharide content of Hib liquid combined vaccines        | 24   |
| 2.4.9 Vaccine prequalification – establishment of the WHO-NNB   | 24   |
| 2.5 Strategic issues  | 25   |
| 2.5.1 Standards for priority pathogens for public health emergencies  | 25   |
| 2.5.2 International standards and reference preparations – revision of TRS 932 Annex 2  | 27   |
| <b>3. International Recommendations, Guidelines and other matters related to the manufacture, quality control and evaluation of biological substances</b> | 29   |
| 3.1 Biotherapeutics other than blood products   | 29   |
| 3.1.1 Guidelines on procedures and data requirements for changes to approved biotherapeutic products  | 29   |

|           |  |           |
|-----------|--|-----------|
| 3.2       | Cellular and gene therapies  | 30        |
| 3.2.1     | Global activities in cell therapy products   | 30        |
| 3.3       | In vitro diagnostics   | 31        |
| 3.3.1     | WHO IVD prequalification: update report  | 31        |
| 3.3.2     | Human immunodeficiency virus rapid diagnostic tests for professional use and/or self-testing   | 33        |
| 3.3.3     | Establishing stability of in vitro diagnostic medical devices  | 34        |
| 3.3.4     | WHO consultation on the First WHO International Standard for anti-rubella immunoglobulin   | 35        |
| 3.4       | Vaccines and related substances  | 36        |
| 3.4.1     | Guidelines on the quality, safety and efficacy of Ebola vaccines   | 36        |
| <b>4.</b> | <b>International reference materials – antibiotics</b>   | <b>38</b> |
| 4.1       | Proposed new projects and updates – antibiotics  | 38        |
| 4.1.1     | Proposed Third WHO International Standard for erythromycin   | 38        |
| <b>5.</b> | <b>International reference materials – biotherapeutics other than blood products</b>   | <b>39</b> |
| 5.1       | WHO International Standards and Reference Reagents – biotherapeutics other than blood products   | 39        |
| 5.1.1     | Second WHO International Standard for parathyroid hormone 1-34 (recombinant, human)  | 39        |
| 5.1.2     | First WHO International Standard for rituximab   | 40        |
| 5.1.3     | First WHO International Standard for infliximab  | 41        |
| <b>6.</b> | <b>International reference materials – blood products and related substances</b>   | <b>44</b> |
| 6.1       | WHO International Standards and Reference Reagents – blood products and related substances   | 44        |
| 6.1.1     | First WHO Reference Reagent for activated blood coagulation factor X (human)   | 44        |
| 6.1.2     | Second WHO International Standard for activated blood coagulation factor IX (human)  | 45        |
| 6.1.3     | First WHO International Standard for blood coagulation factor XII (plasma, human) via assignment of additional analytes to the current Second WHO International Standard for blood coagulation factor XI (plasma, human) | 46        |
| <b>7.</b> | <b>International reference materials – in vitro diagnostics</b>  | <b>48</b> |
| 7.1       | WHO International Standards and Reference Reagents – in vitro diagnostics  | 48        |
| 7.1.1     | First WHO Reference Reagent for lupus anti-dsDNA serum   | 48        |
| 7.1.2     | Third WHO International Standard for hepatitis A virus RNA for NAT-based assays  | 49        |
| 7.1.3     | Fourth WHO International Standard for HIV-1 RNA for NAT-based assays   | 50        |
| 7.1.4     | First WHO International Standard for Ebola virus antibodies (plasma, human); and First WHO Reference Panel for Ebola virus antibodies (plasma, human)  | 51        |
| 7.1.5     | First WHO Reference Panel for genomic KRAS codons 12 and 13 mutations  | 52        |
| 7.1.6     | First WHO International Standard for human herpes virus 6B DNA for NAT-based assays  | 54        |
| 7.1.7     | First WHO International Standard for <i>Plasmodium falciparum</i> antigens   | 55        |

|           |  |           |
|-----------|--|-----------|
| 7.1.8     | First WHO International Standard for anti-cytomegalovirus immunoglobulin G   | 56        |
| 7.1.9     | First WHO International Standard for chikungunya virus RNA for NAT-based assays  | 57        |
| 7.1.10    | First WHO International Standard for Zika virus antibodies (immunoglobulin G and immunoglobulin M) (human)   | 58        |
| 7.2       | Proposed new projects and updates – in vitro diagnostics   | 59        |
| 7.2.1     | Proposed First WHO Reference Panel for cancer mutation detection   | 59        |
| 7.2.2     | Proposed Third WHO International Standard for prekallikrein activator  | 60        |
| 7.2.3     | Proposed First WHO Reference Reagent for anti-human platelet antigen 15b   | 60        |
| 7.2.4     | Proposed First WHO International Standard for anti-cyclic citrullinated peptide antibodies   | 61        |
| 7.2.5     | Proposed Second WHO International Standard for rheumatoid factor   | 62        |
| 7.2.6     | Proposed Second WHO reference reagents for dengue virus subtypes 1–4   | 63        |
| 7.2.7     | Proposed First WHO International Standard for cutaneous leishmaniasis; and First WHO Reference Panel for cutaneous leishmaniasis                                   | 63        |
| 7.2.8     | Proposed First WHO International Standard for <i>Plasmodium vivax</i> antigens; and First WHO Reference Reagent for anti-malaria ( <i>Plasmodium vivax</i> ) serum | 64        |
| 7.2.9     | Proposed First WHO International Standard for anti-MERS-CoV serum  | 65        |
| 7.2.10    | Proposed First WHO International Standard for MERS-CoV RNA for NAT-based assays  | 65        |
| 7.2.11    | Proposed Sixth WHO International Standard for hepatitis C virus RNA for NAT-based assays   | 66        |
| <b>8.</b> | <b>International reference materials – vaccines and related substances</b>   | <b>68</b> |
| 8.1       | WHO International Standards and Reference Reagents – vaccines and related substances   | 68        |
| 8.1.1     | First WHO international standards for oral poliomyelitis vaccines  | 68        |
| 8.1.2     | Second WHO International Standard for pertussis toxin  | 69        |
| 8.1.3     | First WHO international standards for <i>Citrobacter freundii</i> and <i>Salmonella</i> Typhi Vi polysaccharides   | 70        |
| 8.1.4     | First WHO International Standard for anti-typhoid capsular Vi polysaccharide immunoglobulin G (human)  | 72        |
| 8.1.5     | First WHO International Standard for antiserum to respiratory syncytial virus  | 73        |
| 8.2       | Proposed new projects and updates – vaccines and related substances  | 74        |
| 8.2.1     | Proposed First WHO Reference Panel for <i>Vibrio cholera</i> O1 and O139 lipopolysaccharides   | 74        |
| 8.2.2     | Proposed First WHO Reference Panel for anti- <i>Vibrio cholera</i> O1 and O139 lipopolysaccharide serums (rabbit)  | 75        |
| 8.2.3     | Proposed First WHO International Standard for <i>Vibrio cholera</i> vaccine (oral, inactivated)  | 76        |
| 8.2.4     | Proposed First WHO International Standard for antibody to the influenza virus haemagglutinin stem domain   | 76        |
| 8.2.5     | Proposed First WHO international standards for influenza virus pathogenicity for safety testing  | 77        |
| 8.2.6     | Proposed Third WHO International Standard for anti-rabies immunoglobulin (human)   | 78        |

## **Annex 1**

|  |    |
|--|----|
| WHO Recommendations, Guidelines and other documents related to the manufacture, quality control and evaluation of biological substances used in medicine | 81 |
|--|----|

## **Annex 2**

|  |    |
|--|----|
| Guidelines on the quality, safety and efficacy of Ebola vaccines | 87 |
|--|----|

## **Annex 3**

|  |     |
|--|-----|
| Guidelines on procedures and data requirements for changes to approved biotherapeutic products | 181 |
|--|-----|

## **Annex 4**

|  |     |
|--|-----|
| Technical Specifications Series (TSS) for WHO Prequalification – Diagnostic Assessment | 281 |
|--|-----|

## **Annex 5**

|  |     |
|--|-----|
| Technical Guidance Series (TGS) for WHO Prequalification – Diagnostic Assessment | 315 |
|--|-----|

## **Annex 6**

|   |     |
|---|-----|
| Biological substances: WHO International Standards, Reference Reagents and Reference Panels | 377 |
|---|-----|

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>